News

PMA Insights: Week 23

19/05/2021

Author:

Amy Rudd, ACIM
About the Author

Article Tags

Biosimilars Funding HTA Oncology PMA Trends

Share this article

Related articles

Articles
13.04.2026
Don’t Wait for a JSC: Unlocking Value Through H...

While missing an EU Joint Scientific Consultation (JSC) is suboptimal, the greater strategic concern...

Read more
Articles
30.03.2026
From Evidence to Negotiation: Succeeding Under Ita...

From 1 April 2026, AIFA’s updated HTA guidelines will come into effect, making ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch